The role of reactive oxygen species and proinflammatory cytokines in type 1 diabetes pathogenesis

Abstract

Type 1 diabetes (T1D) is a T cell–mediated autoimmune disease characterized by the destruction of insulin‐secreting pancreatic β cells. In humans with T1D and in nonobese diabetic (NOD) mice (a murine model for human T1D), autoreactive T cells cause β‐cell destruction, as transfer or deletion of these cells induces or prevents disease, respectively. CD4 + and CD8 + T cells use distinct effector mechanisms and act at different stages throughout T1D to fuel pancreatic β‐cell destruction and disease pathogenesis. While these adaptive immune cells employ distinct mechanisms for β‐cell destruction, one central means for enhancing their autoreactivity is by the secretion of proinflammatory cytokines, such as IFN‐γ, TNF‐α, and IL‐1. In addition to their production by diabetogenic T cells, proinflammatory cytokines are induced by reactive oxygen species (ROS) via redox‐dependent signaling pathways. Highly reactive molecules, proinflammatory cytokines are produced upon lymphocyte infiltration into pancreatic islets and induce disease pathogenicity by directly killing β cells, which characteristically possess low levels of antioxidant defense enzymes. In addition to β‐cell destruction, proinflammatory cytokines are necessary for efficient adaptive immune maturation, and in the context of T1D they exacerbate autoimmunity by intensifying adaptive immune responses. The first half of this review discusses the mechanisms by which autoreactive T cells induce T1D pathogenesis and the importance of ROS for efficient adaptive immune activation, which, in the context of T1D, exacerbates autoimmunity. The second half provides a comprehensive and detailed analysis of (1) the mechanisms by which cytokines such as IL‐1 and IFN‐γ influence islet insulin secretion and apoptosis and (2) the key free radicals and transcription factors that control these processes.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 195

1. 1.

   van Belle TL, Coppieters KT, von Herrath MG. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol. Rev. 2011;91:79-118.

   Not in our library10.1152/physrev.00003.2010

2. 2.

   Haskins K, et al. Oxidative stress in type 1 diabetes. Ann. N.Y. Acad. Sci. 2003;1005:43-54.

   Not in our library10.1196/annals.1288.006

3. 3.

   Curtsinger JM, et al. Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. J. Immunol. 1999;162:3256-3262.

   Not in our library

4. 4.

   Pape KA, et al. Inflammatory cytokines enhance the in vivo clonal expansion and differentiation of antigen-activated CD4+ T cells. J. Immunol. 1997;159:591-598.

   Not in our library

5. 5.

   Tse HM, Milton MJ, Piganelli JD. Mechanistic analysis of the immunomodulatory effects of a catalytic antioxidant on antigen-presenting cells: implication for their use in targeting oxidation-reduction reactions in innate immunity. Free Radic. Biol. Med. 2004;36:233-247.

   Not in our library10.1016/j.freeradbiomed.2003.10.029

6. 6.

   Patterson CC, et al. Trends in childhood type 1 diabetes incidence in Europe during 1989–2008: evidence of non-uniformity over time in rates of increase. Diabetologia. 2012;55:2142-2147.

   Not in our library10.1007/s00125-012-2571-8

7. 7.

   Patterson CC, et al. Incidence trends for childhood type 1 diabetes in Europe during 1989–2003 and predicted new cases 2005–20: a multicentre prospective registration study. Lancet. 2009;373:2027-2033.

   Not in our library10.1016/s0140-6736(09)60568-7

8. 8.

   Redondo MJ, et al. Concordance for islet autoimmunity among monozygotic twins. N. Engl. J. Med. 2008;359:2849-2850.

   Not in our library10.1056/nejmc0805398

9. 9.

   Banting FG, Best CH. The internal secretion of the pancreas. J. Lab. Clin. Med. 1922;7:465-480.

   Not in our library

10. 10.

    Willcox A, et al. Analysis of islet inflammation in human type 1 diabetes. Clin. Exp. Immunol. 2009;155:173-181.

    Not in our library10.1111/j.1365-2249.2008.03860.x

11. 11.

    Herold KC, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 2002;346:1692-1698.

    Not in our library10.1056/nejmoa012864

12. 12.

    Bougneres PF, et al. Factors associated with early remission of type I diabetes in children treated with cyclosporine. N. Engl. J. Med. 1988;318:663-670.

    Not in our library10.1056/nejm198803173181103

13. 13.

    Keymeulen B, et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia. 2010;53:614-623.

    Not in our library10.1007/s00125-009-1644-9

14. 14.

    Voltarelli JC, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2007;297:1568-1576.

    Not in our library10.1001/jama.297.14.1568

15. 15.
    Cellular Islet Autoimmunity Associates with Clinical Outcome of Islet Cell Transplantation · 2008

    No notice
16. 16.

    Katz J, Benoist C, Mathis D. Major histocompatibility complex class I molecules are required for the development of insulitis in non-obese diabetic mice. Eur. J. Immunol. 1993;23:3358-3360.

    Not in our library10.1002/eji.1830231244

17. 17.

    Serreze DV, et al. Major histocompatibility complex class I-deficient NOD-B2m null mice are diabetes and insulitis resistant. Diabetes. 1994;43:505-509.

    Not in our library10.2337/diab.43.3.505

18. 18.

    Sumida T, et al. Prevention of insulitis and diabetes in beta 2-microglobulin-deficient non-obese diabetic mice. Int. Immunol. 1994;6:1445-1449.

    Not in our library10.1093/intimm/6.9.1445

19. 19.

    Skowera A, et al. CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J. Clin. Invest. 2008;118:3390-3402.

    Not in our library10.1172/jci35449

20. 20.

    Willcox A, et al. Analysis of islet inflammation in human type 1 diabetes. Clin. Exp. Immunol. 2009;155:173-181.

    Not in our library10.1111/j.1365-2249.2008.03860.x

21. 21.

    Wong FS, et al. CD8 T cell clones from young nonobese diabetic (NOD) islets can transfer rapid onset of diabetes in NOD mice in the absence of CD4 cells. J. Exp. Med. 1996;183:67-76.

    Not in our library10.1084/jem.183.1.67

22. 22.

    DiLorenzo TP, et al. Major histocompatibility complex class I-restricted T cells are required for all but the end stages of diabetes development in nonobese diabetic mice and use a prevalent T cell receptor alpha chain gene rearrangement. Proc. Natl. Acad. Sci. USA. 1998;95:12538-12543.

    Not in our library10.1073/pnas.95.21.12538

23. 23.

    Nagata M, et al. Evidence for the role of CD8+ cytotoxic T cells in the destruction of pancreatic beta-cells in nonobese diabetic mice. J. Immunol. 1994;152:2042-2050.

    Not in our library

24. 24.

    Dudek NL, et al. Cytotoxic T-cells from T-cell receptor transgenic NOD8.3 mice destroy beta-cells via the perforin and Fas pathways. Diabetes. 2006;55:2412-2418.

    Not in our library10.2337/db06-0109

25. 25.

    Graser RT, et al. Identification of a CD8 T cell that can independently mediate autoimmune diabetes development in the complete absence of CD4 T cell helper functions. J. Immunol. 2000;164:3913-3918.

    Not in our library10.4049/jimmunol.164.7.3913

26. 26.

    Wong FS, et al. Activation of insulin-reactive CD8 T-cells for development of autoimmune diabetes. Diabetes. 2009;58:1156-1164.

    Not in our library10.2337/db08-0800

27. 27.

    Wang B, et al. The role of CD8+ T cells in the initiation of insulin-dependent diabetes mellitus. Eur. J. Immunol. 1996;26:1762-1769.

    Not in our library10.1002/eji.1830260815

28. 28.

    Podack ER, et al. Function of granule perforin and esterases in T cell-mediated reactions. Components required for delivery of molecules to target cells. Ann. N.Y. Acad. Sci. 1988;532:292-302.

    Not in our library10.1111/j.1749-6632.1988.tb36347.x

29. 29.

    Savinov AY, et al. Contribution of Fas to diabetes development. Proc. Natl. Acad. Sci. USA. 2003;100:628-632.

    Not in our library10.1073/pnas.0237359100

30. 30.

    Hamilton-Williams EE, et al. Beta cell MHC class I is a late requirement for diabetes. Proc. Natl. Acad. Sci. USA. 2003;100:6688-6693.

    Not in our library10.1073/pnas.1131954100

31. 31.

    Shizuru JA, et al. Immunotherapy of the nonobese diabetic mouse: treatment with an antibody to T-helper lymphocytes. Science. 1988;240:659-662.

    Not in our library10.1126/science.2966437

32. 32.

    Haskins K, et al. Pancreatic islet-specific T-cell clones from nonobese diabetic mice. Proc. Natl. Acad. Sci. USA. 1989;86:8000-8004.

    Not in our library10.1073/pnas.86.20.8000

33. 33.

    Katz JD, et al. Following a diabetogenic T cell from genesis through pathogenesis. Cell. 1993;74:1089-1100.

    Not in our library10.1016/0092-8674(93)90730-e

34. 34.

    Stadinski BD, et al. Chromogranin A is an autoantigen in type 1 diabetes. Nat. Immunol. 2010;11:225-231.

    Not in our library10.1038/ni.1844

35. 35.

    Christianson SW, Shultz LD, Leiter EH. Adoptive transfer of diabetes into immunodeficient NOD-scid/scid mice. Relative contributions of CD4+ and CD8+ T-cells from diabetic versus prediabetic NOD.NON-Thy-1a donors. Diabetes. 1993;42:44-55.

    Not in our library10.2337/diab.42.1.44

36. 36.

    Thivolet C, et al. CD8+ T cell homing to the pancreas in the nonobese diabetic mouse is CD4+ T cell-dependent. J. Immunol. 1991;146:85-88.

    Not in our library

37. 37.

    Yagi H, et al. Analysis of the roles of CD4+ and CD8+ T cells in autoimmune diabetes of NOD mice using transfer to NOD athymic nude mice. Eur. J. Immunol. 1992;22:2387-2393.

    Not in our library10.1002/eji.1830220931

38. 38.

    Varanasi V, et al. Cytotoxic mechanisms employed by mouse T cells to destroy pancreatic β-cells. Diabetes. 2012;61:2862-2870.

    Not in our library10.2337/db11-1784

39. 39.

    Thomas HE, et al. Beta cell apoptosis in diabetes. Apoptosis. 2009;14:1389-1404.

    Not in our library10.1007/s10495-009-0339-5

40. 40.

    Campbell IL, et al. Essential role for interferon-gamma and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice. J. Clin. Invest. 1991;87:739-742.

    Not in our library10.1172/jci115055

Cited by papers we hold 9

• Mechanisms of Oxidative Stress in Metabolic Syndrome · 2023
  No notice
• The role of inflammation in immune system of diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications · 2022
  No notice
• Mitophagy protects β cells from inflammatory damage in diabetes · 2020
  No notice
• Regulation of Cytokine Production by the Unfolded Protein Response; Implications for Infection and Autoimmunity · 2018
  No notice
• Neutrophil Extracellular Traps and Its Implications in Inflammation: An Overview · 2017
  No notice
• Role of Pro-Inflammatory Cytokines and Biochemical Markers in the Pathogenesis of Type 1 Diabetes: Correlation with Age and Glycemic Condition in Diabetic Human Subjects. · 2016
  Not checked
• Suppressors of cytokine signaling in sickness and in health of pancreatic β-cells · 2016
  Not checked
• NSC23766, a Known Inhibitor of Tiam1-Rac1 Signaling Module, Prevents the Onset of Type 1 Diabetes in the NOD Mouse Model · 2016
  Not checked
• Calcium-independent phospholipases A2 and their roles in biological processes and diseases · 2015
  Not checked

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.